Amgen Inc.'s Repatha and Sanofi/Regeneron Pharmaceuticals Inc.'s Praluent are still struggling to get off the ground – but there is hope ahead for the PCSK9 inhibitors in terms of better labeling and better positioning in treatment guidelines for cholesterol reduction due in early September.
PCSK9 Sales Still Slow, But May Get Boost From Label, Guideline Changes
Amgen's report of higher sales and news of priority review for an outcomes benefit claim for Repatha bode well, but a negative JAMA editorial is another knock on the PCSK9 inhibitor class.
More from New Products
More from Scrip
• By
By allowing it to enter the brain more easily, trontinemab’s brain shuttle brings more patients to ‘amyloid zero’ levels faster, and with fewer brain swelling side effects.
• By
Compass' bispecific antibody tovecimig hits primary efficacy endpoint in Phase II/III top-line data in advanced biliary tract cancer, and may have class side-effect advantages. But additional survival data may be needed to support US approval.
• By
AstraZeneca remains committed to investing in R&D and alliances in China, where Susan Galbraith, the UK major’s head of oncology R&D, sees innovation eventually reaching parity with the US and Europe.